Home Clinical and Healthcare Professional Hub Clinical Research Publications Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis

14 / 06 / 21

Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis


Abstract

Background: Owing to its physical properties, intensity-modulated proton therapy (IMPT) used for patients with oropharyngeal carcinoma has the ability to reduce the dose to organs at risk compared to intensity-modulated radiotherapy (IMRT) while maintaining adequate tumour coverage. Our aim was to compare the clinical outcomes of these two treatment modalities.

Methods: We performed a 1:2 matching of IMPT to IMRT patients. Our study cohort consisted of IMPT patients from a prospective quality of life study and consecutive IMRT patients treated at a single institution during the period 2010-2014. Patients were matched on unilateral/bilateral treatment, disease site, human papillomavirus status, T and N status, smoking status, and receipt of concomitant chemotherapy. Survival analyzes were performed using a Cox model and binary toxicity endpoints using a logistic regression analysis.

Results: Fifty IMPT and 100 IMRT patients were included. The median follow-up time was 32months. There were no imbalances in patient/tumor characteristics except for age (mean age 56.8years for IMRT patients and 61.1years for IMPT patients, p-value=0.010). Statistically significant differences were not observed in overall survival (hazard ratio (HR)=0.55; 95% confidence interval (CI): 0.12-2.50, p-value=0.44) or in progression-free survival (HR=1.02; 95% CI: 0.41-2.54; p-value=0.96). The age-adjusted odds ratio (OR) for the presence of a gastrostomy (G)-tube during treatment for IMPT vs IMRT were OR=0.53; 95% CI: 0.24-1.15; p-value=0.11 and OR=0.43; 95% CI: 0.16-1.17; p-value=0.10 at 3months after treatment. When considering the pre-planned composite endpoint of grade 3 weight loss or G-tube presence, the ORs were OR=0.44; 95% CI: 0.19-1.0; p-value=0.05 at 3months after treatment and OR=0.23; 95% CI: 0.07-0.73; p-value=0.01 at 1year after treatment.

Conclusion: Our results suggest that IMPT is associated with reduced rates of feeding tube dependency and severe weight loss without jeopardizing outcome. Prospective multicenter randomized trials are needed to validate such findings.

Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, Crutison J, Lee JJ, Ye R, Fuller CD, Mohamed AS, Hutcheson KA, Holliday EB, Thaker NG, Sturgis EM, Kies MS, Zhu XR, Mohan R, Frank SJ. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol. 2016 Jul;120(1):48-55. doi: 10.1016/j.radonc.2016.05.022. Epub 2016 Jun 21. PMID: 27342249; PMCID: PMC5474304.

*Please refer to the Terms and Conditions of this website when leaving the site and viewing third party content. 

Consultants we currently work with (head & neck)

Dr Josef Kovarik

Dr Josef Kovarik is an acting consultant clinical oncologist and a Lead of ENT Oncology at the Northern Centre for Cancer...

Read more
Dr Josef Kovarik

Dr Russell Banner

Dr Russell Banner is a Consultant Clinical Oncologist based in South Wales. His undergraduate training was at Christ’s College, Cambridge...

Read more
Dr Russell Banner

Dr Shanmugasundaram Ramkumar

Dr Ramkumar is a Consultant Clinical Oncologist specialising in non-surgical treatment of Head and Neck cancer, Skull Base Tumours and...

Read more
Dr Shanmugasundaram Ramkumar

Dr Muthiah Sivaramalingam

Dr Muthiah Sivaramalingam has been a consultant in Clinical Oncology since 2007 and has been Principal Investigator for many clinical...

Read more
Dr Muthiah Sivaramalingam

Dr Cheng Boon

Dr Cheng Boon is Consultant Clinical Oncologist at the Worcester Oncology Centre at Worcester Royal Hospital. He completed medical training...

Read more
Dr Cheng Boon

Dr Eleanor Aynsley

Dr Aynsley graduated from Leeds Medical School in 1999. She did medical training in Durham, gaining MRCP in 2004. She...

Read more
Dr Eleanor Aynsley

Cancer treatments we offer

The Rutherford Cancer Centres provide high-quality cancer care by offering access to innovative and advanced treatment techniques using leading technology.

Consultants we work with

We provide exceptional patient support from diagnosis through to treatment and recovery, with leading consultants available at our centres across the country.

Centres across the UK

The Rutherford Cancer Centres provide cancer treatments and other healthcare services across the UK with our centres designed to put the patient experience first.

Contact Us

Get in Touch

If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or

Our Trusted Healthcare Partners